These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
723 related articles for article (PubMed ID: 25624727)
21. Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials. Zaanan A; Shi Q; Taieb J; Alberts SR; Meyers JP; Smyrk TC; Julie C; Zawadi A; Tabernero J; Mini E; Goldberg RM; Folprecht G; Van Laethem JL; Le Malicot K; Sargent DJ; Laurent-Puig P; Sinicrope FA JAMA Oncol; 2018 Mar; 4(3):379-383. PubMed ID: 28983557 [TBL] [Abstract][Full Text] [Related]
22. FOXP3+ regulatory T cells, mismatch repair proteins and BRAF V600E status in young-onset colorectal cancer. Isah Tsamiya R; Mohd Nafi SN; Che Jalil NA; Mat Zin AA Malays J Pathol; 2024 Aug; 46(2):233-246. PubMed ID: 39207001 [TBL] [Abstract][Full Text] [Related]
23. Next-generation sequencing reveals heterogeneous genetic alterations in key signaling pathways of mismatch repair deficient colorectal carcinomas. Wang J; Li R; He Y; Yi Y; Wu H; Liang Z Mod Pathol; 2020 Dec; 33(12):2591-2601. PubMed ID: 32620917 [TBL] [Abstract][Full Text] [Related]
24. Distinct Clinicopathological Patterns of Mismatch Repair Status in Colorectal Cancer Stratified by KRAS Mutations. Li W; Zhi W; Zou S; Qiu T; Ling Y; Shan L; Shi S; Ying J PLoS One; 2015; 10(6):e0128202. PubMed ID: 26042813 [TBL] [Abstract][Full Text] [Related]
25. Clinicopathologic features and prognostic value of KRAS, NRAS and BRAF mutations and DNA mismatch repair status: A single-center retrospective study of 1,834 Chinese patients with Stage I-IV colorectal cancer. Guo TA; Wu YC; Tan C; Jin YT; Sheng WQ; Cai SJ; Liu FQ; Xu Y Int J Cancer; 2019 Sep; 145(6):1625-1634. PubMed ID: 31162857 [TBL] [Abstract][Full Text] [Related]
26. Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H). Goldstein J; Tran B; Ensor J; Gibbs P; Wong HL; Wong SF; Vilar E; Tie J; Broaddus R; Kopetz S; Desai J; Overman MJ Ann Oncol; 2014 May; 25(5):1032-8. PubMed ID: 24585723 [TBL] [Abstract][Full Text] [Related]
27. Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy. Sinicrope FA; Mahoney MR; Smyrk TC; Thibodeau SN; Warren RS; Bertagnolli MM; Nelson GD; Goldberg RM; Sargent DJ; Alberts SR J Clin Oncol; 2013 Oct; 31(29):3664-72. PubMed ID: 24019539 [TBL] [Abstract][Full Text] [Related]
28. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study. André T; de Gramont A; Vernerey D; Chibaudel B; Bonnetain F; Tijeras-Raballand A; Scriva A; Hickish T; Tabernero J; Van Laethem JL; Banzi M; Maartense E; Shmueli E; Carlsson GU; Scheithauer W; Papamichael D; Möehler M; Landolfi S; Demetter P; Colote S; Tournigand C; Louvet C; Duval A; Fléjou JF; de Gramont A J Clin Oncol; 2015 Dec; 33(35):4176-87. PubMed ID: 26527776 [TBL] [Abstract][Full Text] [Related]
29. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. Hutchins G; Southward K; Handley K; Magill L; Beaumont C; Stahlschmidt J; Richman S; Chambers P; Seymour M; Kerr D; Gray R; Quirke P J Clin Oncol; 2011 Apr; 29(10):1261-70. PubMed ID: 21383284 [TBL] [Abstract][Full Text] [Related]
30. [Effects of tumor location and mismatch repair on clinicopathological features and survival for non-metastatic colon cancer: A retrospective, single center, cohort study]. Sun Z; Zhou WX; Li KX; Wu B; Lin GL; Qiu HZ; Niu BZ; Sun XY; Lu JY; Xu L; Xiao Y Zhonghua Wei Chang Wai Ke Za Zhi; 2024 Jun; 27(6):591-599. PubMed ID: 38901992 [No Abstract] [Full Text] [Related]
31. Mitochondrial DNA Copy Number as a Biomarker for Guiding Adjuvant Chemotherapy in Stages II and III Colorectal Cancer Patients with Mismatch Repair Deficiency: Seeking Benefits and Avoiding Harms. Chen M; Deng S; Cao Y; Wang J; Zou F; Gu J; Mao F; Xue Y; Jiang Z; Cheng D; Huang N; Huang L; Cai K Ann Surg Oncol; 2024 Sep; 31(9):6320-6330. PubMed ID: 38985229 [TBL] [Abstract][Full Text] [Related]
32. A relationship to survival is seen by combining the factors of mismatch repair status, tumor location and age of onset in colorectal cancer patients. Li P; Xiao Z; Braciak TA; Ou Q; Chen G; Oduncu FS PLoS One; 2017; 12(3):e0172799. PubMed ID: 28253296 [TBL] [Abstract][Full Text] [Related]
33. High prevalence of deficient mismatch repair phenotype and the V600E BRAF mutation in elderly patients with colorectal cancer. Aparicio T; Schischmanoff O; Poupardin C; Mary F; Soufir N; Barrat C; Bellaiche G; Boubaya M; Choudat L; Cucherousset J; DesGuetz G; Wind P; Benamouzig R J Geriatr Oncol; 2014 Oct; 5(4):384-8. PubMed ID: 25176643 [TBL] [Abstract][Full Text] [Related]
34. Tumour infiltrating lymphocyte status is superior to histological grade, DNA mismatch repair and BRAF mutation for prognosis of colorectal adenocarcinomas with mucinous differentiation. Williams DS; Mouradov D; Newman MR; Amini E; Nickless DK; Fang CG; Palmieri M; Sakthianandeswaren A; Li S; Ward RL; Hawkins NJ; Skinner I; Jones I; Gibbs P; Sieber OM Mod Pathol; 2020 Jul; 33(7):1420-1432. PubMed ID: 32047231 [TBL] [Abstract][Full Text] [Related]
35. [Difference analysis of somatic mutations between deficient mismatch repair and proficient mismatch repair gene related with colorectal cancer]. Tang XJ; Yang MY; Zhu LZ; Xu D; Yuan Y Zhonghua Zhong Liu Za Zhi; 2021 Oct; 43(10):1088-1093. PubMed ID: 34695900 [No Abstract] [Full Text] [Related]
36. Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials. Sinicrope FA; Shi Q; Allegra CJ; Smyrk TC; Thibodeau SN; Goldberg RM; Meyers JP; Pogue-Geile KL; Yothers G; Sargent DJ; Alberts SR JAMA Oncol; 2017 Apr; 3(4):472-480. PubMed ID: 28006055 [TBL] [Abstract][Full Text] [Related]
37. Sporadic deficient mismatch repair in colorectal cancer increases the risk for non-colorectal malignancy: A European multicenter cohort study. Gkekas I; Jan N; Kaprio T; Beilmann-Lehtonen I; Fabian P; Tavelin B; Böckelman C; Edin S; Strigård K; Svoboda T; Hagström J; Barsova L; Jirasek T; Haglund C; Palmqvist R; Gunnarsson U J Surg Oncol; 2024 Jun; 129(7):1295-1304. PubMed ID: 38470492 [TBL] [Abstract][Full Text] [Related]
38. Association between molecular subtypes of colorectal cancer and patient survival. Phipps AI; Limburg PJ; Baron JA; Burnett-Hartman AN; Weisenberger DJ; Laird PW; Sinicrope FA; Rosty C; Buchanan DD; Potter JD; Newcomb PA Gastroenterology; 2015 Jan; 148(1):77-87.e2. PubMed ID: 25280443 [TBL] [Abstract][Full Text] [Related]
39. BRAF mutations in colorectal cancer are associated with distinct clinical characteristics and worse prognosis. Kalady MF; Dejulius KL; Sanchez JA; Jarrar A; Liu X; Manilich E; Skacel M; Church JM Dis Colon Rectum; 2012 Feb; 55(2):128-33. PubMed ID: 22228154 [TBL] [Abstract][Full Text] [Related]
40. Molecular patterns in deficient mismatch repair colorectal tumours: results from a French prospective multicentric biological and genetic study. Etienne-Grimaldi MC; Mahamat A; Chazal M; Laurent-Puig P; Olschwang S; Gaub MP; Formento JL; Formento P; Sudaka A; Boige V; Abderrahim-Ferkoune A; Benchimol D; André T; Houry S; Faucheron JL; Letoublon C; Gilly FN; Delpero JR; Lasser P; Pradere B; Pezet D; Penault-Llorca F; Milano G Br J Cancer; 2014 May; 110(11):2728-37. PubMed ID: 24800948 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]